Patents by Inventor Bhagwat Prasad

Bhagwat Prasad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUANTITATION OF GLA PROTEINS BY MASS SPECTROMETRIC ANALYSIS
    Publication number: 20220034901
    Abstract: Methods of LC-MS/MS quantification of ?-carboxylated proteins in plasma, serum, or blood, including dried blood spots, are disclosed. The methods can be used to determine patient-specific dosing of anticoagulant drugs and diagnosis of liver diseases, such as hepatocellular carcinoma.
    Type: Application
    Filed: July 27, 2021
    Publication date: February 3, 2022
    Applicants: University of Washington, Washington State University
    Inventors: Bhagwat Prasad, Kenneth E. Thummel, Abdul Basit Shaikh, Allan E. Rettie
  • Methods for treating testosterone deficiency in men and methods for precise dosing of UGT2B17 substrate drugs
    Patent number: 11131677
    Abstract: Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: September 28, 2021
    Assignee: University of Washington
    Inventors: Bhagwat Prasad, Abdul Basit, Haeyoung Zhang, John K. Amory
  • METHODS FOR TREATING TESTOSTERONE DEFICIENCY IN MEN AND METHODS FOR PRECISE DOSING OF UGT2B17 SUBSTRATE DRUGS
    Publication number: 20190307773
    Abstract: Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided.
    Type: Application
    Filed: April 10, 2019
    Publication date: October 10, 2019
    Applicant: University of Washington
    Inventors: Bhagwat Prasad, Abdul Basit, Haeyoung Zhang, John K. Amory